Qilian International Holding Group Limited (BGM)vsTeva Pharma Industries Ltd ADR (TEVA)
BGM
Qilian International Holding Group Limited
$0.26
-4.57%
HEALTHCARE · Cap: $105.36M
TEVA
Teva Pharma Industries Ltd ADR
$37.09
+3.34%
HEALTHCARE · Cap: $42.84B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 36046% more annual revenue ($17.32B vs $47.90M). TEVA leads profitability with a 4.1% profit margin vs -44.2%. TEVA earns a higher WallStSmart Score of 49/100 (D+).
BGM
Hold36
out of 100
Grade: F
TEVA
Hold49
out of 100
Grade: D+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 69.8% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Earnings expanding 72.2% YoY
Growing faster than its price suggests
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -0.8% — below average capital efficiency
4.1% margin — thin
Operating margin of 4.0%
Premium valuation, high expectations priced in
Revenue declined 0.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : BGM
The strongest argument for BGM centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 69.8% demonstrates continued momentum.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.67 suggests the stock is reasonably priced for its growth.
Bear Case : BGM
The primary concerns for BGM are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : TEVA
The primary concerns for TEVA are Profit Margin, Operating Margin, P/E Ratio. A P/E of 61.3x leaves little room for execution misses. Debt-to-equity of 2.18 is elevated, increasing financial risk.
Key Dynamics to Monitor
BGM profiles as a hypergrowth stock while TEVA is a value play — different risk/reward profiles.
BGM carries more volatility with a beta of 1.46 — expect wider price swings.
BGM is growing revenue faster at 69.8% — sustainability is the question.
TEVA generates stronger free cash flow (307M), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (49/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Qilian International Holding Group Limited
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company is headquartered in Jiuquan, the People's Republic of China.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?